Literature DB >> 31823412

Angiotensin II-induced micro RNA-21 culprit for non-small-cell lung adenocarcinoma.

Zhaoji Luan1, Baoliang Liu1, Lina Shi2.   

Abstract

Lung cancer is among the most complicated cancers, with an estimated 1.6 million deaths each year for both men and women. However, the proportion of lung cancer patients in developing nations has increased from 31% to 49.9% in the last two decades. There are two main subtypes of lung cancer, small-cell lung carcinoma and non-small-cell lung carcinoma (NSCLC), accounting for 15% and 85% of all lung cancer, respectively. Adenocarcinoma is the most common type of lung cancer in smokers and nonsmokers in men and women regardless of their age. Chemicals in cigarette smoke and nicotine enter our bloodstream and can then affect the entire body and finally lead to the activation of several important, pro-survival signaling pathways. The biologically active peptide of RAAS on overstimulation enhance Ang II mediates cell proliferation, fibrosis and inflammatory effects via AT1 receptor. Very few studies highlight the diagnostic and therapeutic potential of miRNAs with the EGFR-regulated miRNA-21.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  NSCLC; cigarette smoking; lung carcinoma; miRNA-21; renin-angiotensin-aldosterone system

Mesh:

Substances:

Year:  2019        PMID: 31823412     DOI: 10.1002/ddr.21597

Source DB:  PubMed          Journal:  Drug Dev Res        ISSN: 0272-4391            Impact factor:   4.360


  2 in total

1.  Prognostic value of PD-1, PD-L1 and P53 in patients with non-small cell lung cancer after postoperative adjuvant chemoradiotherapy.

Authors:  Aizhong Qu; Jiliang Han; Jianfeng Zhu
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

Review 2.  The Effect of Local Renin Angiotensin System in the Common Types of Cancer.

Authors:  Moudhi Almutlaq; Abir Abdullah Alamro; Hassan S Alamri; Amani Ahmed Alghamdi; Tlili Barhoumi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-03       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.